Bruker Launches CellScape XR for Enhanced Diagnostic Spatial Proteomics
Bruker has launched CellScape XR, a spatial proteomics platform designed to enhance diagnostic and prognostic analyses through high-resolution imaging mass spectrometry. The system aims to accelerate biomarker discovery workflows and enable clinical translation of proteomic insights.
1. Launch of CellScape XR Platform
On February 25, 2026, Bruker introduced CellScape XR, its next-generation spatial proteomics solution geared toward diagnostic and prognostic research. The rollout marks a strategic expansion of Bruker’s life sciences portfolio into high-resolution imaging mass spectrometry for clinical applications.
2. Technology Capabilities and Applications
CellScape XR integrates enhanced spatial resolution with advanced proteomic workflows to map protein distributions in tissue samples. The platform is positioned to accelerate biomarker discovery, streamline translational research, and support precision medicine initiatives in oncology and immunology.